Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | ODC1 | P11926 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27660494 | 0.68 | KDM4E (0.40) | CA1CA7CA9CA2MAPT | |
| SCHEMBL2879152 | 0.66 | CA1 (0.42) | CA1CA7CA9CA2MAPT | |
| SCHEMBL27660464 | 0.64 | SMN1; SMN2 (0.39) | MAPTKDM4ELMNATDP1MEN1 | |
| SCHEMBL27567584 | 0.63 | MAPT (0.40) | CA1CA7CA9CA2MAPT | |
| SCHEMBL28350683 | 0.63 | KDM4E (0.35) | CA1CA7CA9CA2ODC1 | |
| SCHEMBL11575259 | 0.63 | HDAC4 (0.60) | CA1CA7CA9CA2MAPT | |
| SCHEMBL23655043 | 0.61 | ALDH1A1 (0.48) | CA1CA7CA9CA2MAPT | |
| SCHEMBL9146000 | 0.60 | CA1 (0.49) | CA1CA7CA9CA2MAPT | |
| SCHEMBL5532838 | 0.59 | NPC1 (0.44) | ODC1MAPTKDM4ELMNATDP1 | |
| SCHEMBL14482096 | 0.59 | TYMS (0.54) | MAPTKDM4ELMNATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | claimed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | claimed |
| EP-2331093-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | The Trustees of Columbia University in the City of New York (US) | 2011-06-15 | — | — | EP | claimed |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-05-26 | — | — | US | claimed |
| WO-2010025272-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-04 | — | — | WO | claimed |
| WO-2009105123-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-08-27 | — | — | WO | claimed |
| WO-2008103916-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | claimed |
| WO-2000035865-A2 | TUBULIN-BINDING AGENTS | TULARIK INC. (US) | 2000-06-22 | — | — | WO | claimed |
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | disclosed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2331093-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | The Trustees of Columbia University in the City of New York (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-05-26 | — | — | US | disclosed |
| US-20110081325-A1 | NOVEL TREATMENT OF HEART DISEASES | AXIOGENESIS AG (DE) | 2011-04-07 | — | — | US | disclosed |
| EP-2280710-A2 | NOVEL TREATMENT OF HEART DISEASES | Axiogenesis Ag (DE) | 2011-02-09 | — | — | EP | disclosed |
| US-20050215764-A1 | Biological polymer with differently charged portions | TECHNOLOGY INNOVATIONS, LLC | 2005-09-29 | — | — | US | disclosed |
| US-6433187-B1 | ANTIMOTOSIS AGENT | TULARIK INC. | 2002-08-13 | — | — | US | disclosed |
| US-6433187-B1 | ANTIMOTOSIS AGENT | TULARIK INC. | 2002-08-13 | — | — | US | disclosed |
| WO-2000035865-A3 | TUBULIN-BINDING AGENTS | TULARIK INC (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000035865-A2 | TUBULIN-BINDING AGENTS | TULARIK INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035865-A2 | TUBULIN-BINDING AGENTS | TULARIK INC. (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | TUBA1C, TUBB1, TOP1 | CA1 2566/4885CA7 2493/4885CA9 2833/4885 |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | BDNF, NGF, NTRK2 | CA1 977/4885CA7 3252/4885CA9 3439/4885 |
| US-20050215764-A1 | Biological polymer with differently charged portions | TUBB3, TUBB1, TUBB | CA1 294/4885CA7 504/4885CA9 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.